# Sodium Chloride

## Sodium chloride 0.9% inj 1000mL

| 藥物代碼 | INS1 |
| :--- | :--- |
| 適應症 | 為食鹽水沖洗液\(A001085209\) |
| 副作用 | NA |
| 禁忌 | NA |
| 藥物保存方式 | 室溫 |
| 用法用量 | Individualised dosage. |
| 肝功能異常 | 無需調整劑量  需調整劑量 |
| 腎功能異常 | 無需調整劑量  需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IRR, IRRI, IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## Isotonic NaCl inj 20mL

| 藥物代碼 | INS2 |
| :--- | :--- |
| 適應症 | 為生理食鹽水\(N009997238\) |
| 副作用 | NA |
| 禁忌 | NA |
| 藥物保存方式 | 室溫 |
| 用法用量 | 20-100 mL SC/IV/IV infusion. May use as diluent. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | EXT, IH, IM, IRR, IVD, IVPUSH, LI, SC |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## 0.9% NaCl inj  250mL

| 藥物代碼 | INS250 |
| :--- | :--- |
| 適應症 | 為生理食鹽水注射液\(A001085265\) |
| 副作用 | NA |
| 禁忌 | NA |
| 藥物保存方式 | 室溫 |
| 用法用量 | IV infusion as needed. |
| 肝功能異常 | 無需調整劑量  需調整劑量 |
| 腎功能異常 | 無需調整劑量  需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IRR, IRRI, IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## 3% NaCl inj 500mL

| 藥物代碼 | INS3 |
| :--- | :--- |
| 適應症 | ■Corneal edema■Hyponatremia■Hypovolemic shock |
| 副作用 | common■Cardiovascular: Phlebitis■Dermatologic: Injection site extravasation, Injection site reaction■Endocrine metabolic: Hypervolemia serious■Cardiovascular: Congestive heart failure■Endocrine metabolic: Hypernatremia, Overhydration■Hematologic: Disseminated intravascular coagulation■Respiratory: Respiratory distress |
| 禁忌 | Hypersensitivity to sodium chloride or any component of the formulation; hypertonic uterus, hypernatremia, fluid retention |
| 藥物保存方式 | 室溫 |
| 用法用量 | IV infusion as needed. ■Hyponatremia: chronic hyponatremia, severe symptoms: increase serum sodium by 2 to 4 mmol/L within 2 to 4 hr \(1 to 2 mmol/L/hr\) with infusion of hypertonic saline; limit corrections of sodium level to less than 10 to 12 mmol/L in 24 hours, and to less than 18 mmol/L in 48 hours to avoid demyelination syndrome \(guideline dosing\). |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | micromedex: Pregnancy category:C |
| 注射劑給藥建議途徑 | IH, IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 1. 本藥品為高張輸注液，須特別注意給藥速率。 |

## 0.45% Saline inj 500mL

| 藥物代碼 | INS45 |
| :--- | :--- |
| 適應症 | 為0.45 % 食鹽水注射液\(A036014277\) |
| 副作用 | NA |
| 禁忌 | NA |
| 藥物保存方式 | 室溫 |
| 用法用量 | IV infusion as needed. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## 0.9% NaCl inj  500mL

| 藥物代碼 | INS5 |
| :--- | :--- |
| 適應症 | 為生理食鹽水注射液\(A001085277\) |
| 副作用 | NA |
| 禁忌 | NA |
| 藥物保存方式 | 室溫 |
| 用法用量 | IV infusion as needed. |
| 肝功能異常 | 無需調整劑量  需調整劑量 |
| 腎功能異常 | 無需調整劑量  需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IRR, IRRI, IV, IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## 0.9% NaCl 100mL bag\(Otsuka\)

| 藥物代碼 | INSO100 |
| :--- | :--- |
| 適應症 | Water or electrolyte replenishment. |
| 副作用 | CommonCardiovascular: PhlebitisDermatologic: Injection site extravasation, Injection site reactionEndocrine metabolic: HypervolemiaSeriousCardiovascular: Congestive heart failureEndocrine metabolic: Hypernatremia, OverhydrationHematologic: Disseminated intravascular coagulationRespiratory: Respiratory distress |
| 禁忌 | Hypernatremic and fluid retention syndromes. Immediately following surgery. |
| 藥物保存方式 | 30℃以下 |
| 用法用量 | Individualised dosage. Sodium chloride 0.9% irrigation solution contains 154 mEq/L sodium and 154 mEq/L chloride. Calculated osmolarity is 308 mOsmol/L. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | \[仿單\]沒有資料 |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | \[仿單\]沒有資料 |
| 注射劑給藥建議途徑 | IA, IRR, IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | To correct acute \(48 hours or duration unknown\). In general, a serum sodium concentration increase of 4 to 6 mEq/L within a 24-hour period is sufficient to improve most symptoms of hyponatremia. In chronic severe hyponatremia, overcorrection risks iatrogenic osmotic demyelination syndrome. Goal of initial therapy is to increase serum sodium concentration by 4 to 6 mEq/L within the first 24 hours \(maximum rate: 8 mEq/L in any 24-hour period\). |
| 注意事項 | 0.9% Sodium chloride solution contains 154 mEq/L sodium and 154 mEq/L chloride. Calculated osmolarity is 308 mOsmol/L. |

## 0.9% NaCl 250mL bag\(Otsuka\)

| 藥物代碼 | INSO250 |
| :--- | :--- |
| 適應症 | Water or electrolyte replenishment. |
| 副作用 | CommonCardiovascular: PhlebitisDermatologic: Injection site extravasation, Injection site reactionEndocrine metabolic: HypervolemiaSeriousCardiovascular: Congestive heart failureEndocrine metabolic: Hypernatremia, OverhydrationHematologic: Disseminated intravascular coagulationRespiratory: Respiratory distress |
| 禁忌 | Hypernatremic and fluid retention syndromes. Immediately following surgery. |
| 藥物保存方式 | 30℃以下 |
| 用法用量 | Individualised dosage. Sodium chloride 0.9% irrigation solution contains 154 mEq/L sodium and 154 mEq/L chloride. Calculated osmolarity is 308 mOsmol/L. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | \[仿單\]沒有資料 |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | \[仿單\]沒有資料 |
| 注射劑給藥建議途徑 | IA, IRR, IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | To correct acute \(48 hours or duration unknown\). In general, a serum sodium concentration increase of 4 to 6 mEq/L within a 24-hour period is sufficient to improve most symptoms of hyponatremia. In chronic severe hyponatremia, overcorrection risks iatrogenic osmotic demyelination syndrome. Goal of initial therapy is to increase serum sodium concentration by 4 to 6 mEq/L within the first 24 hours \(maximum rate: 8 mEq/L in any 24-hour period\). |
| 注意事項 | 0.9% Sodium chloride solution contains 154 mEq/L sodium and 154 mEq/L chloride. Calculated osmolarity is 308 mOsmol/L. |

## 0.9% NaCl 500mL bag\(Otsuka\)

| 藥物代碼 | INSO5 |
| :--- | :--- |
| 適應症 | Water or electrolyte replenishment. |
| 副作用 | CommonCardiovascular: PhlebitisDermatologic: Injection site extravasation, Injection site reactionEndocrine metabolic: HypervolemiaSeriousCardiovascular: Congestive heart failureEndocrine metabolic: Hypernatremia, OverhydrationHematologic: Disseminated intravascular coagulationRespiratory: Respiratory distress |
| 禁忌 | Hypernatremic and fluid retention syndromes. Immediately following surgery. |
| 藥物保存方式 | 30℃以下 |
| 用法用量 | Individualised dosage. Sodium chloride 0.9% irrigation solution contains 154 mEq/L sodium and 154 mEq/L chloride. Calculated osmolarity is 308 mOsmol/L. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | \[仿單\]沒有資料 |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | \[仿單\]沒有資料 |
| 注射劑給藥建議途徑 | IA, IRR, IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | To correct acute \(48 hours or duration unknown\). In general, a serum sodium concentration increase of 4 to 6 mEq/L within a 24-hour period is sufficient to improve most symptoms of hyponatremia. In chronic severe hyponatremia, overcorrection risks iatrogenic osmotic demyelination syndrome. Goal of initial therapy is to increase serum sodium concentration by 4 to 6 mEq/L within the first 24 hours \(maximum rate: 8 mEq/L in any 24-hour period\). |
| 注意事項 | 0.9% Sodium chloride solution contains 154 mEq/L sodium and 154 mEq/L chloride. Calculated osmolarity is 308 mOsmol/L. |

